(331 days)
Not Found
No
The device description focuses on the electrosurgical system's hardware components and the delivery of radio frequency energy. There is no mention of AI or ML in the intended use, device description, or the sections specifically checked for AI/ML terms. The performance study describes clinical outcomes, not the performance of an AI/ML algorithm.
Yes
The device is intended for dermatologic and general surgical procedures involving electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles, which are all therapeutic interventions.
No
The device is intended for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles, which are surgical procedures rather than diagnostic ones. It delivers RF energy to cause tissue coagulation, which is a therapeutic action.
No
The device description clearly outlines hardware components including a system main body, LCD touch screen, RF generator, power supply, handpiece, and foot switch. It is an electrosurgical system that delivers RF energy via hardware.
Based on the provided information, the VIVACE Electrosurgical System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for dermatologic and general surgical procedures for electrocoagulation, hemostasis, and the percutaneous treatment of facial wrinkles. This involves direct interaction with the patient's tissue for therapeutic purposes.
- Device Description: The device delivers radio frequency energy to the tissue to cause an electrothermal reaction. This is a physical intervention on the body.
- Lack of In Vitro Activity: There is no mention of the device being used to examine specimens (like blood, urine, tissue samples) outside of the body to provide information about a patient's health status.
IVD devices are specifically designed to perform tests on samples taken from the human body to diagnose diseases or other conditions. The VIVACE Electrosurgical System is a therapeutic device that directly treats tissue.
N/A
Intended Use / Indications for Use
The VIVACE Electrosurgical System is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles. This Vivace Electrosurgical System is intended for use with Skin Type I to Skin Type V.
Product codes
OUH
Device Description
The VIVACE Electrosurgical System is comprised of the following components: the system main body of the device which consists of the LCD touch screen control panel, the high frequency generating output section (main P.C.B board or RF Generator), and the power supply component, the Switching Power Supply (SMPS). The accessories to the device include the handpiece with disposable micro-needle cartridge (electrode) insertion, and foot switch. Radio frequency current (RF energy) is delivered from the RF Generator, through the handpiece and electrode tip into the target tissue. The hand piece being held at right angles, the tip is placed in light contact with the epidermis. As RF energy passes through the skin, it generates an electro thermal reaction, which is capable of coagulating (causing minor dermal damage) the tissue. The bi-polar RF energy is delivered between independent adjacent electrode pairs (total 36 needle electrode, 6 x 6 array insertion). The RF generator, hand piece are not disposable. Each disposable micro-needle cartridge (electrode) is supplied sterile and is for single patient use only and cannot be resterilized.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
facial wrinkles, peri-oral, periorbital, skin
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The study had 31 participants with 28 subjects completing all three sessions and are included in the final study analysis. The data were evaluated against baseline at 30 days. 60 days and 90 days by three. blinded, independent licensed physicians using the 9-point Fitzpatrick Wrinkle and Elastosis scale scoring methodology for the peri-oral and periorbital regions. The scores showed improvement over the 90 day period after treatments. Among the 3 blinded evaluators, by 2/3 evaluator agreement (>= 1 point change) criteria, 17 out of 28 (60.7%) subjects had one point improvement at 90 day follow up.
Adverse Events that occurred in greater than 5% of the subjects were Erythema (77.42%), Edema (19.35%), Edema (16.13%), and Sensitivity (6.45%). Adverse event cases decreased with each re-treatment phase for all AE types and were resolved within 24 hours. Overall adverse event rates were highest at the first treatment cycle, decreasing by a third after the second treatment and with little to no AEs reported after the third and final treatment (from 70.97% at treatment cycle 1 down to 6.45% at treatment cycle 3). Across treatments, each AE consistently decreased after the first, second and third (final) treatment cycles for every AE.
Most of the patients felt less pain overall through 3 treatment cycles. At 1st treatment cycle, for the peri-orbital wrinkle area, 9/28 subjects experienced pain at level 1-3 (32%) range, 12/28 at level 4 to 6 (43%) range, and 7/28 at level 7 to 10 (25%) range. During 3rd treatment cycle, 15/28 subjects reported experiencing pain at levels 1-3(53%), 12/28 at levels 4 to 6 (43%), and 1/28 at levels over 8 (3.5%).
The data shows gradual wrinkle class improvement at 90 days. The scores and change in wrinkle class demonstrate improvement in rhytids and in solar elastosis. The independent blinded evaluations support post treatment efficacy based on the Fitzpatrick Wrinkle Scores. All studied parameters suggest a favorable treatment profile of the VIVACE device to reduce wrinkles in the peri-orbital and peri-oral regions. The device showed moderate, but positive improvement in wrinkle severity and elastosis damage.
Key Metrics
Among the 3 blinded evaluators, by 2/3 evaluator agreement (>= 1 point change) criteria, 17 out of 28 (60.7%) subjects had one point improvement at 90 day follow up.
Predicate Device(s)
INFINI Radiofrequency System (K121481)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4400 Electrosurgical cutting and coagulation device and accessories.
(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features the department's name in a circular arrangement around a stylized image of three human profiles. The profiles are stacked on top of each other and are connected by a flowing line that resembles a ribbon or a wave.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 15, 2016
Sung Hwan E&B Company, Ltd % Mr. Kachi Enyinna 510K Technology Group, LLC 263 Huntington Avenue, #332 Boston, Massachusetts 02115
Re: K150409
Trade/Device Name: VIVACE Electrosurgical System Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: Class II Product Code: OUH Dated: November 30, 2015 Received: December 3, 2015
Dear Mr. Enyinna:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Jennifer R. Stevenson -S
For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K150409
Device Name
VIVACE Electrosurgical System
Indications for Use (Describe)
The VIVACE Electrosurgical System is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles. This Vivace Electrosurgical System is intended for use with Skin Type I to Skin Type V.
| Type of Use (Select one or both, as applicable) |
|---|
| ☒Prescription Use (Part 21 CFR 801 Subpart D) ☐Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
3
Sung Hwan E&B Co., Ltd.
Vivace Electrosurgical System 510(k) Notification
510(k) Summary
This 510(k) Summary is in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content of this 510(k) summary is provided in conformance with 21 CFR Part 807.92.
I. Sponsor's Information
| Name: | Sung Hwan E&B Co., Ltd. | ||
|---|---|---|---|
| Address: | Suite #502, SK Techno Bldg | ||
| 16-4 Sung Su-Dong 1 Ga | |||
| Sung Dong Ku, Seoul Korea | |||
| Phone: | 82-2-466-0010 | ||
| Fax: | 82-2-466-5473 | ||
| Contact Person: | Sun Young Kang | ||
| Tel: 82-2-466-0010 | |||
| Fax: 82-2-466-5473 | |||
| Email: ksy66820@naver.com | |||
| Official Correspondent: | Kachi Enyinna, MS | ||
| Principal Consultant | |||
| 510K Technology Group, LLC | |||
| 263 Huntington Avenue, Suite 332 | |||
| Boston, MA 02115 | |||
| (240) 994-4242 | |||
| Date Prepared: | January 6, 2016 | ||
| II. Device Name | |||
| Trade Name: | VIVACE | ||
| Common Name: | Electrosurgical System and Accessories | ||
| Classification Name: | Electrosurgical Cutting and Coagulation device and | ||
| Accessories | |||
| Classification Number: | 21 CFR 878.4400 | ||
| Product Code: | OUH | ||
| Classification Panel: | General and Plastic Surgery |
III. Predicate Device
The VIVACE Electrosurgical System is substantially equivalent to the INFINI Radiofrequency System (K121481).
4
IV. Intended Use
The VIVACE Electrosurgical System is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles. This Vivace Electrosurgical System is intended for use with Skin Type I to Skin Type V.
V. Device Description
The VIVACE Electrosurgical System is comprised of the following components: the system main body of the device which consists of the LCD touch screen control panel, the high frequency generating output section (main P.C.B board or RF Generator), and the power supply component, the Switching Power Supply (SMPS). The accessories to the device include the handpiece with disposable micro-need le cartridge (electrode) insertion, and foot switch. Radio frequency current (RF energy) is delivered from the RF Generator, through the handpiece and electrode tip into the target tissue. The hand piece being held at right angles, the tip is placed in light contact with the epidermis. As RF energy passes through the skin, it generates an electro thermal reaction, which is capable of coagulating (causing minor dermal damage) the tissue. The bi-polar RF energy is delivered between independent adjacent electrode pairs (total 36 needle electrode, 6 x 6 array insertion). The RF generator, hand piece are not disposable. Each disposable micro-needle cartridge (electrode) is supplied sterile and is for single patient use only and cannot be resterilized.
| Electrical voltage and frequency | AC 230V 50/60 Hz | |
|---|---|---|
| Power conception | 40 VA | |
| Maximum output current | 62mA ± 20% (load resistance | |
| 500Ω | ||
| Maximum output voltage | 134V ± 20% (load resistance | |
| 500Ω | ||
| Accuracy of the output frequency | 1 MHz | |
| Microneedle | ||
| Cartridge | Electrode | |
| Exposed | ||
| length | 36 each, 6 x 6 array | |
| 0.5 ~ 3.5mm (0.1mm increments) | ||
| Outer | ||
| diameter | ∅0.3mm | |
| Weight | ||
| Dimension | (W)380mm x (L)340mm x | |
| (H)1200mm |
VI. Technical Specifications
5
VII. Performance Data
Electrical safety test, Electromagnetic compatibility test, Sterility, and Biocompatibility testing were completed to demonstrate the safety and performance of the VIVACE Electrosurgical System.
Tests were performed on the Vivace Electrosrugical System and its sterile disposable single use micro-needle cartridge. The biological safety of the device has been demonstrated through biocompatibility studies of all patient contact materials in accordance with the standards outlined in IS010993-1
Results of the clinical testing demonstrated that the VIVACE Electrosurgical System is safe and effective for its intended use. The micro-need le cartridge is supplied sterile and sterility conforms to a Sterility Assurance Level (SAL) of 10° . The supplied Instructions for Use provide the user with the applicable warnings and cautions during use. There are no new safety or effectiveness issues related to this device.
VIII. Clinical Summary
The study had 31 participants with 28 subjects completing all three sessions and are included in the final study analysis. The data were evaluated against baseline at 30 days. 60 days and 90 days by three. blinded, independent licensed physicians using the 9-point Fitzpatrick Wrinkle and Elastosis scale scoring methodology for the peri-oral and periorbital regions. The scores showed improvement over the 90 day period after treatments. Among the 3 blinded evaluators, by 2/3 evaluator agreement (≥ 1 point change) criteria, 17 out of 28 (60.7%) subjects had one point improvement at 90 day follow up.
Adverse Events that occurred in greater than 5% of the subjects were Erythema (77.42%), Edema (19.35%), Edema (16.13%), and Sensitivity (6.45%). Adverse event cases decreased with each re-treatment phase for all AE types and were resolved within 24 hours. Overall adverse event rates were highest at the first treatment cycle, decreasing by a third after the second treatment and with little to no AEs reported after the third and final treatment (from 70.97% at treatment cycle 1 down to 6.45% at treatment cycle 3). Across treatments, each AE consistently decreased after the first, second and third (final) treatment cycles for every AE.
6
Sung Hwan E&B Co., Ltd.
Vivace Electrosurgical System 510(k) Notification
Most of the patients felt less pain overall through 3 treatment cycles. At 1st treatment cycle, for the peri-orbital wrinkle area, 9/28 subjects experienced pain at level 1-3 (32%) range, 12/28 at level 4 to 6 (43%) range, and 7/28 at level 7 to 10 (25%) range. During 3rd treatment cycle, 15/28 subjects reported experiencing pain at levels 1-3(53%), 12/28 at levels 4 to 6 (43%), and 1/28 at levels over 8 (3.5%). We hypothesize that the decrease in pain may be related to tissue coagulation and increased dermal thickness from initial exposure to RF energy treatment. During the 7-10 day interval, histological changes in the dermis may affect sensitivity during follow up treatment cycles with increase to RF energy.
The data shows gradual wrinkle class improvement at 90 days. The scores and change in wrinkle class demonstrate improvement in rhytids and in solar elastosis. The independent blinded evaluations support post treatment efficacy based on the Fitzpatrick Wrinkle Scores. All studied parameters suggest a favorable treatment profile of the VIVACE device to reduce wrinkles in the peri-orbital and peri-oral regions. The device showed moderate, but positive improvement in wrinkle severity and elastosis damage.
IX. Conclusion
The intended use of the VIVACE Electrosurgical System is substantially equivalent to the predicate device in intended use, design and RF technology. The clinical study demonstrates that the VIVACE functions as intended with no significant impact on the safety and effectiveness profile of the device for the treatment of facial wrinkles.
Data to support substantial equivalence to the predicate device was generated in a clinical study. The clinical study was designed to demonstrate the Vivace device is safe and effective for the treatment of facial wrinkles. Clinical data from a 31 patient US study using a validated scale, Fitzpatrick Wrinkle Severity Scale, supported substantial equivalence of the VIVACE to the predicate device for the percutaneous treatment of facial wrinkles in peri-oral and peri-orbital regions.